AVBP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AVBP is not a clear buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock has a constructive longer-term setup because analyst sentiment is bullish and the pipeline catalyst is important, but the current technicals are mixed and there is no fresh news or proprietary buy signal to justify an immediate purchase. If the investor is impatient and wants to act now, I would still choose hold rather than buy because the current entry is not strong enough relative to the near-term uncertainty around the next trial readout.
The technical picture is mixed. SMA_5 > SMA_20 > SMA_200 is bullish and suggests the broader trend remains intact, but the MACD histogram is -0.349 and negatively expanding, which points to weakening momentum. RSI_6 at 33.912 is near oversold but not yet a strong reversal signal. Price at 28.83 is just above S1 at 28.492 and below the pivot at 30.02, showing the stock is trading below a key short-term reference level. The candlestick pattern stats also lean weak, with downside probability over the next day, week, and month.
["Citi raised its price target to $45 and expects positive Phase 3 FURVENT data in Q2 or Q3.", "B. Riley also raised its target to $45, citing improved confidence in the EGFR TKI class.", "BTIG initiated with a Buy and $42 target, calling the stock materially discounted to a successful FURVENT outcome.", "Oppenheimer raised its target to $50 and highlighted the mid-2026 pivotal readout as a meaningful catalyst.", "Options positioning is heavily bullish, suggesting traders are anticipating upside ahead of the trial catalyst.", "No negative news was reported in the last week, which keeps the setup catalyst-focused."]
["No news in the recent week means there is no fresh catalyst already confirming momentum.", "MACD momentum is weakening and currently negative.", "Price is below the pivot level, showing near-term technical softness.", "The stock pattern analysis suggests downside probabilities over the next day, week, and month.", "Revenue remains at 0, so the company is still pre-commercial and dependent on pipeline execution.", "No recent congress trading data or insider buying support is available.", "Hedge funds and insiders are both neutral, so there is no strong smart-money accumulation signal."]
In Q4 2025, the company reported revenue of 0, so there is no commercial revenue base yet. Net income was -35.54 million, though that loss improved 72.27% year over year. EPS was -0.83, also improving 36.07% year over year. This shows operating losses are still present, but losses are narrowing, which is typical for a late-stage biotech focused on development rather than sales. Latest quarter season: 2025 Q4.
Analyst sentiment is clearly positive. Recent coverage and target increases have clustered around $42 to $50, with Citi, B. Riley, BTIG, Oppenheimer, and H.C. Wainwright all maintaining Buy/Outperform-style ratings. The main bullish thesis is the upcoming FURVENT Phase 3 readout, which multiple firms believe could drive substantial upside. Wall Street pros are positive because the market may be underestimating the trial outcome and the drug's positioning in EGFR exon 20 insertion NSCLC. The con side is that the entire valuation hinges on a binary clinical catalyst and there is no current revenue support.
